An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT compliant)

• Published in: Medicine (Baltimore) Vol. 99; no. 50; p. e23291
• Main Authors: Koga, Tomohiro, Takemori, Sachiko, Hagimori, Naoko, Morimoto, Shimpei, Sumiyoshi, Remi, Shimizu, Toshimasa, Hosogaya, Naoki, Fukushima, Chizu, Yamamoto, Hiroshi, Kawakami, Atsushi
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 11.12.2020
• Subjects: Antibodies, Monoclonal, Humanized - therapeutic use; Castleman Disease - drug therapy; Double-Blind Method; Humans; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sirolimus - adverse effects; Sirolimus - therapeutic use; Study Protocol Clinical Trial; Treatment Failure; Treatment Outcome

Interleukin 6 (IL-6) inhibitors are the first-line treatment for idiopathic multicentric Castleman disease (iMCD); however, there is no established treatment for cases that are resistant to IL-6 inhibitors. Although sirolimus, a mammalian target of rapamycin inhibitor, has been suggested to be effec...